ArriVent BioPharma, Inc.
As of Oct 22, 2026, ArriVent BioPharma is in Stage 4, the downtrend phase, now in its first week (since Oct 19, 2026). It closed at $19.20, 44.7% below its 52-week high and below its 200-day average, which is falling.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is AVBP early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AVBP among Biotechnology197th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …197 | AVBP | Stage 4 · wk 1 | 52 | −36.6% |
ArriVent BioPharma: quick answers
What stage is ArriVent BioPharma in?
As of Oct 22, 2026, ArriVent BioPharma (AVBP) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 19, 2026 and is in its first week there. What the four stages mean
Is ArriVent BioPharma in an uptrend?
No. ArriVent BioPharma is in a Stage 4 downtrend. It trades 29.1% below its 200-day average, which is falling.
How far is ArriVent BioPharma from its 52-week high?
ArriVent BioPharma closed at $19.20 on Oct 22, 2026, 44.7% below its 52-week high of $34.74. Its 52-week low is $15.09.
How has ArriVent BioPharma performed over the past year?
As of Oct 22, 2026, ArriVent BioPharma is down 2.0% over the past year and down 7.7% so far in 2026.
Which sector and industry is ArriVent BioPharma in?
ArriVent BioPharma is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.